Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Randomized controlled multi-center trial of multi-periscopic prism glasses for hemianopia: early results
Author Affiliations & Notes
  • Eli Peli
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Sailaja Manda
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Sandhya Shekar
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Alex D. Hwang
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Jae-Hyun Jung
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Sara McWilliams
    Ophthalmology, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States
  • David Simpson
    Ophthalmology, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States
  • Tracy Lynn Matchinski
    Optometry, Illinois College of Optometry, Chicago, Illinois, United States
  • Jem Martin
    Department of Specialty and Advanced Care, New England College of Optometry, Boston, Massachusetts, United States
  • Scott Hearing
    Optometry, Visual Health and Surgical Center/Quigley Eye Associates, Palm Springs, Florida, United States
  • Maheen Sharfuddin
    Optometry, Visual Health and Surgical Center/Quigley Eye Associates, Palm Springs, Florida, United States
  • Alex R Bowers
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Eli Peli Schepens, Chadwick Optical, Code P (Patent); Sailaja Manda None; Sandhya Shekar None; Alex Hwang None; Jae-Hyun Jung None; Sara McWilliams None; David Simpson None; Tracy Matchinski None; Jem Martin None; Scott Hearing None; Maheen Sharfuddin None; Alex Bowers None
  • Footnotes
    Support  NIH grant EY023385
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4328. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eli Peli, Sailaja Manda, Sandhya Shekar, Alex D. Hwang, Jae-Hyun Jung, Sara McWilliams, David Simpson, Tracy Lynn Matchinski, Jem Martin, Scott Hearing, Maheen Sharfuddin, Alex R Bowers; Randomized controlled multi-center trial of multi-periscopic prism glasses for hemianopia: early results. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4328.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Multi-periscopic peripheral prisms (MPP) are a novel, high-power field expansion reflective device for homonymous hemianopia (HH). We are conducting a multi-center trial to evaluate the MPPs for general mobility with a virtual reality pedestrian collision detection test - a randomized crossover design in which (100Δ, ~42°) MPP glasses are being compared to commercially available (65Δ, ~32°) Fresnel peripheral prism (FPP) glasses, both in the oblique design. We hypothesize that detection of colliding overtaken pedestrians at 40° bearing angles will be higher with MPPs.

Methods : Patients (with HH and neither neglect nor cognitive decline) are being recruited at 7 sites. Eligible patients are randomly allocated to receive either 1) MPP first and FPP second, or 2) FPP first and MPP second. There are 4 visits: V1 screening; V2 fitting 1st pair of prism glasses; V3 evaluation of 1st pair (after 4 weeks of home wear) and fitting 2nd pair; V4 evaluation of 2nd pair (after 4 weeks) and clinical decision whether to continue with one pair for the longer term. A collision detection test, presented on a large screen (104° H by 74° V), simulates walking through a busy shopping mall with multiple pedestrians walking in various directions; in each trial one pedestrian might be on a collision course. Patients whose detection without devices on the blindside was > 70% were excluded. Questionnaires documented patients’ experience with the devices.

Results : To date, 25 patients have been screened, 9 were ineligible, 2 withdrew and 14 enrolled (48±22 years, 10 Male), 6 have completed and kept one device (3 chose MPPs, 3 FPPs). Median detection rates for these 6 patients for pedestrians at 40° and 20° bearing angles, with and with NO prisms on the same visits are shown in the table (image).
All 6 reported benefits with MPP and FPP for mobility/obstacle avoidance, 3/6 had difficulty interpreting prism image with FPPs/MPPs, 5/6 rated MPPs much better in terms of image clarity and how far to the blind side they could see, but worse than FPP for appearance. Early data suggests some learning effects in performing the task without prisms.

Conclusions : Recruitment and enrolment are progressing well. A large proportion were excluded at screening because with detection rates > 70% on the blind side there was no possibility for a significant improvement with prisms. Updated data will be presented at the meeting.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×